Identification through high‐throughput screening of 4'‐methoxyflavone and 3',4'‐dimethoxyflavone as novel neuroprotective inhibitors of parthanatos
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background and Purpose: The current lack of disease‐modifying therapeutics to manage neurological and neurodegenerative conditions justifies the development of more efficacious agents. One distinct pathway leading to neuronal death in these conditions and which represents a very promising and attractive therapeutic target is parthanatos, involving overactivation of PARP‐1. We therefore sought to identify small molecules that could be neuroprotective by targeting the pathway. Experimental Approach: Using H e L a cells, we developed and optimized an assay for high‐throughput screening of about 5120 small molecules. Structure–activity relationship (SAR) study was carried out in H e L a and SH‐SY5Y cells for molecules related to the initial active compound. The neuroprotective ability of each active compound was tested in cortical neuronal cultures. Key Results: 4'‐Methoxyflavone (4MF) showed activity by preventing the decrease in cell viability of H e L a and SH‐SY5Y cells caused by the DNA‐alkylating agent,N‐methyl‐N‘‐nitro‐N‐nitrosoguanidine (MNNG), which induces parthanatos. A similar compound from the SAR study, 3',4'‐dimethoxyflavone (DMF), also showed significant activity. Both compounds reduced the synthesis and accumulation of poly (ADP‐ribose) polymer and protected cortical neurones against cell death induced by NMDA. Conclusions and Implications: Our data reveal additional neuroprotective members of the flavone class of flavonoids and show that methoxylation of the parent flavone structure at position 4′ confers parthanatos‐inhibiting activity while additional methoxylation at position 3′, reported by others to improve metabolic stability, does not destroy the activity. These molecules may therefore serve as leads for the development of novel neurotherapeutics for the management of neurological and neurodegenerative conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002) · Science · doi:10.1126/science.1072221 · Cited by 1,826 · cited 11×
“Our assay development exploited caspase independency as one of the distinguishing features of our target pathway; and the experimental conditions used in both cell lines and neurones were optimized to specifically induce parthanatos, as earlier reported (Yu et al., 2002).”
BackgroundMethodResultSelf-citationParthanatos, a messenger of death
David, K. K. (2009) · Frontiers in Bioscience · doi:10.2741/3297 · Cited by 450 · cited 2×
“…NN G + 12 .5 M NN G + 25 M NN G + 50 M NN G + 10 0 V ia b ili ty ( % c o n tr o l) E F Flavone 3′,4′-dimethoxyflavone 4′-methoxyflavone ## ## # *** British Journal of Pharmacology (2013) 169 1263–1278 1271 et al., 2008), with NMDA inducing parthanatos in a cascade of events (David et al., 2009).”
BackgroundDugas, A. J., Castañeda-Acosta, J., Bonin, G. C., Price, K. L., Fischer, N. H., & Winston, G. W. (2000) · Journal of Natural Products · doi:10.1021/np990352n · Cited by 319
Inhibition of Angiogenesis by the Antifungal Drug Itraconazole
Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., & Liu, J. O. (2007) · ACS Chemical Biology · doi:10.1021/cb600362d · Cited by 210 · cited 1×
“…30% natural products and 20% other bioac- tives), while JHDL is a collection of about 3120 drugs approved by US Food and Drug Administration or its foreign counterparts or drugs that have entered phase II clinical trials (Chong et al., 2007; an overall total of about 5120 small molecules).”
BackgroundSelf-citation
Cited by
Regulated necrosis: disease relevance and therapeutic opportunities
Conrad, M., Angeli, J. P. F., Vandenabeele, P., & Stockwell, B. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.6 · Cited by 630
Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities
Fatokun, A. A., Dawson, V. L., & Dawson, T. M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12416 · Cited by 594
Self-citationWang, C., Ward, M. E., Chen, R., Liu, K., Tracy, T. E., Chen, X., Xie, M., Sohn, P. D., Ludwig, C., Meyer-Franke, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.019 · Cited by 400
“However, HTS requires large numbers of cells and has been largely restricted to immortalized human neuronal lines, such as neuroblastoma SH-SY5Y(Jain et al., 2012) and gliomaH4 (Albrecht et al., 2004) cells, or non-neuronal lines, such as HeLa cells (Fatokun et al., 2013).”
BackgroundThe therapeutic potential of targeting regulated non-apoptotic cell death
Hadian, K., & Stockwell, B. R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00749-8 · Cited by 320
Metadata
- Authors
- Fatokun, A. A., Liu, J. O., Dawson, V. L., & Dawson, T. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-06-21
- Volume
- 169
- Issue
- 6
- Pages
- 1263-1278
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1501041661
- Cited by
- 45
- References
- 4
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.